GHRP-6 vs Hexarelin
Hunger-inducing GH secretagogue vs most potent GHRP with cardioprotective effects — comparing two classic growth hormone releasing peptides.
Last updated: 2026-03-08
Quick Comparison Table
| Category | GHRP-6 | Hexarelin |
|---|---|---|
| Potency (GH Release) | High | Highest among GHRPs |
| Appetite Stimulation | Very strong (major side effect) | Moderate |
| Cortisol Elevation | Moderate | Moderate-high |
| Prolactin Elevation | Moderate | Moderate |
| Unique Property | Intense hunger stimulation | Cardioprotective (CD36 receptor) |
| Desensitisation | Moderate (weeks-months) | Significant (4-8 weeks) |
| Administration | SC injection 2-3x daily | SC injection 2-3x daily |
| Ideal Use Case | GH + appetite stimulation (underweight/catabolic) | Maximum GH + cardiac research |
Mechanism of Action
GHRP-6
GHRP-6 Mechanism:
GHRP-6 (His-D-Trp-Ala-Trp-D-Phe-Lys-NH₂) is a synthetic hexapeptide GH secretagogue.
Key actions: 1. **GHS-R1a activation** — Potent ghrelin receptor agonism, stimulating GH release 2. **Intense appetite stimulation** — The strongest appetite effect among GHRPs, driven by ghrelin receptor activation in the hypothalamus and vagal afferents 3. **Cortisol/prolactin elevation** — Moderate increases at GH-releasing doses 4. **Gastric motility** — Increases gastric acid secretion and gut motility 5. **IGF-1 elevation** — Secondary to GH release
GHRP-6's intense appetite stimulation makes it both a limitation (for body composition goals) and an advantage (for catabolic or underweight patients needing caloric intake support).
Hexarelin
Hexarelin Mechanism:
Hexarelin (His-D-2-Methyl-Trp-Ala-Trp-D-Phe-Lys-NH₂) is the most potent peptide GH secretagogue.
Key actions: 1. **GHS-R1a activation** — Most potent GH release among all GHRPs 2. **CD36 receptor activation** — Unique cardioprotective pathway independent of GH 3. **Cardiac remodelling** — Reduces fibrosis and hypertrophy in heart failure models 4. **Cortisol/prolactin elevation** — Moderate-high at effective doses 5. **Desensitisation** — GH response diminishes 50-80% after 4-8 weeks of continuous use
Hexarelin's CD36-mediated cardioprotection is unique among GHRPs and represents a distinct therapeutic potential beyond GH release.
Clinical Trial Evidence
GHRP-6 Clinical Studies
Design: Randomised controlled trial
This suggests that thyroid hormone excess interferes with GH-releasing pathways activated by these peptides. Our results also suggest that ghrelin's ability to increase glucose levels is not altered in thyrotoxicosis.
View study — PubMed 17410412Design: Randomised controlled trial
Participants: 9 participants
These data show that GH responses to GHRP-6 are much greater than to GHRH in late adulthood. The marked increase of plasma GH levels observed after administration of GHRP-6 alone or in combination with GHRH indicates that impaired GH secretion in late adulthood is a functional and potentially reversible state.
View study — PubMed 7734029Design: Clinical trial
It is concluded that hyperglycemia significantly reduces GH response to combined administration of GHRH+GHRP-6 in normal weight patients with type 2 diabetes. It is suggested that ambient glucose levels should be taken into account during interpretation of GH response to combined administration of GHRH+GHRP-6 in patients with type 2 diabetes.
View study — PubMed 14693411Design: Review
The results using insulin, IGF-I and GHRP-6 given topically are particularly intriguing. Whether these results can be replicated in humans and whether the use of these drugs for potential treatment of obesity will be commercially viable will be particularly interesting.
View study — PubMed 21413905Hexarelin Clinical Studies
Design: Randomised controlled trial
Participants: 7 participants
Ghrelin shows no interaction with HEX, whereas it has a synergistical effect with GHRH on GH secretion. Thus, ghrelin is a new hormone playing a major role in the control of somatotroph secretion in humans, and its effects are imitated by nonnatural GHS.
View study — PubMed 11238504Design: Randomised controlled trial
These data suggest that either the hexarelin or desmopressin test can be used to differentiate patients with Cushing's disease from subjects with alcohol-dependent pseudo-Cushing's syndrome.
View study — PubMed 10886488Design: Randomised controlled trial
In conclusion, the present results demonstrate that in humans Tyr-Ala-HEX is a GH secretagogue as potent as HEX and GHRP-2, two GHRP-6 superanalogs. Tyr-Ala-HEX also shares with HEX and GHRP-2 the same PRL- ACTH- and cortisol-releasing activity.
View study — PubMed 10195374Design: Randomised controlled trial
These findings suggest that in man, the acute administration of Hexarelin exerts a short-lasting, positive inotropic effect. This effect seems GH-independent and might be mediated by specific GHS myocardial receptors.
View study — PubMed 10342360Benefits Comparison
GHRP-6 Unique Benefits
- Intense appetite stimulation (therapeutic in wasting)
- Reliable GH release
- Validated GH deficiency diagnostic
- Less desensitisation than Hexarelin
- Gastric motility enhancement
Shared Benefits
- GH secretagogue activity
- Cortisol/prolactin elevation
- Compatible with GHRH analogues
- Injectable peptides with established pharmacology
Hexarelin Unique Benefits
- Most potent GH release among GHRPs
- Unique cardioprotective activity (CD36)
- Anti-fibrotic cardiac effects
- Anti-atherosclerotic properties
- Dual mechanism (GH + cardiac)
Research & Evidence
GHRP-6 Research
GHRP-6 is well-studied as a GH secretagogue and diagnostic tool. Its appetite-stimulating properties have been explored for wasting conditions. However, it has not progressed to therapeutic approval due to non-selectivity.
Hexarelin Research
Hexarelin's cardioprotective effects via CD36 represent a unique research avenue beyond GH secretion. This has generated sustained research interest despite the desensitisation limitation. No other GHRP has this cardiac profile.
Head-to-Head Analysis
Classic GHRP Comparison:
Both are "first-generation" GHRPs with broad receptor activity.
GH Release: Hexarelin is the most potent GHRP for acute GH release — approximately 30-50% more GH than GHRP-6 at equivalent doses.
Key Differentiator — Appetite: GHRP-6 causes intense, almost immediate hunger after injection. Hexarelin produces moderate appetite stimulation. For patients seeking weight gain, GHRP-6's hunger effect is beneficial; for body composition, it's a significant limitation.
Key Differentiator — Desensitisation: Hexarelin desensitises significantly faster (4-8 weeks) than GHRP-6 (weeks-months), requiring cycling. This limits Hexarelin's use for sustained GH elevation.
Key Differentiator — Cardioprotection: Hexarelin's CD36 activation is unique and not shared by GHRP-6 or any other GHRP.
Protocol Comparison
GHRP-6 Protocol
GHRP-6 Theoretical Protocols:
Dosing: 100-300mcg SC, 2-3x daily. Timing: On empty stomach (30 min before meals for maximal GH + appetite effect). Duration: Can be used continuously for weeks-months with gradual desensitisation.
⚠️ Warning: Intense hunger begins within 15-20 minutes of injection.
Hexarelin Protocol
Hexarelin Theoretical Protocols:
Dosing: 100-200mcg SC, 1-3x daily. Cycling Required: 4-8 weeks on, 4-8 weeks off due to desensitisation. Combination: Often used with CJC-1295 for synergistic GH release.
⚠️ Note: GH response diminishes significantly after 4-8 weeks of continuous use.
Safety Profiles
GHRP-6 Safety
GHRP-6 Safety:
Common: Intense hunger (20-30 minutes post-injection), water retention, cortisol elevation, prolactin increase. Gastric discomfort possible.
Main practical concern: Uncontrollable appetite may lead to weight gain rather than body recomposition.
Hexarelin Safety
Hexarelin Safety:
Common: Moderate appetite increase, cortisol and prolactin elevation, water retention.
Desensitisation is the primary safety/efficacy concern — requiring cycling protocols.
Cardioprotective effects suggest a favourable cardiac safety profile.
The Verdict
GHRP-6 and Hexarelin serve different niches within the GHRP family. Hexarelin wins on raw GH-releasing potency and offers unique cardioprotective benefits via CD36, but its rapid desensitisation limits sustained use. GHRP-6's intense appetite stimulation is either its greatest weakness (body composition goals) or greatest strength (wasting conditions). For maximum acute GH release and cardiac research, Hexarelin is preferred. For sustained GH support with appetite stimulation, GHRP-6 is more practical. Most researchers have migrated toward Ipamorelin for its cleaner profile.
Frequently Asked Questions
Conclusion
GHRP-6 and Hexarelin are classic first-generation GHRPs with distinct profiles — GHRP-6 for appetite-dependent applications and sustained use, Hexarelin for maximum GH potency and unique cardiac research. Both have been largely superseded by Ipamorelin for general GH research due to its superior selectivity, but each retains a niche: GHRP-6 for wasting conditions where appetite is therapeutic, and Hexarelin for cardioprotective research that no other GHRP can address.
Medical Disclaimer
The information provided in this comparison is for educational and research purposes only. Neither GHRP-6 nor Hexarelin is approved for human therapeutic use by the MHRA, EMA, or FDA. This content does not constitute medical advice. Always consult a qualified healthcare professional before considering any peptide or supplement.